Clinical Trial Update: Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of leronlimab (PRO 140) in nonalcoholic steatohepatitis (NASH) has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Leronlimab (PRO 140) (leronlimab)

Snippet

Sponsor: CytoDyn, Inc. | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2023-03-01